Prosecution Insights
Last updated: April 19, 2026
Application No. 17/777,909

METHODS OF ADMINISTERING VOXELOTOR

Final Rejection §102
Filed
May 18, 2022
Examiner
SANCHEZ, JUSTIN CHRISTOPHER
Art Unit
1622
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Global Blood Therapeutics Inc.
OA Round
2 (Final)
84%
Grant Probability
Favorable
3-4
OA Rounds
3y 5m
To Grant
94%
With Interview

Examiner Intelligence

Grants 84% — above average
84%
Career Allow Rate
27 granted / 32 resolved
+24.4% vs TC avg
Moderate +10% lift
Without
With
+10.0%
Interview Lift
resolved cases with interview
Typical timeline
3y 5m
Avg Prosecution
27 currently pending
Career history
59
Total Applications
across all art units

Statute-Specific Performance

§101
0.9%
-39.1% vs TC avg
§103
29.0%
-11.0% vs TC avg
§102
19.1%
-20.9% vs TC avg
§112
31.6%
-8.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 32 resolved cases

Office Action

§102
DETAILED ACTION Claims 1-15 and 17-24, submitted 27 January 2026, are pending in the application. Claims 17-24 remain withdrawn. Claims 1-15 remain rejected. Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Rejections – Maintained The status of the rejections in the previous Office Action are set out below. Rejections under 35 U.S.C. § 103 Applicant asserts that Hutchaleelaha et al. should not be admissible as prior art under 35 U.S.C. 102(a)(1) due to the reference being first published 11 February 2019. Applicant additionally notes that the instant application claims priority to provisional applications 62/940,154, filed on 25 November 2019, and 62/937,706 filed on 19 November 2019. However, the Applicant did not include a statement in the specification at the time of filing and has not provided a declaration to invoke a 102(b)(1)(A) exception. Consequently, the rejections of the previous Office Action are maintained and the pending claims under examination (i.e., claims 1-15) remain rejected. To overcome the rejection, the Applicant could provide a declaration stating that they are invoking a 102(b) exception. See MPEP § 2153.01(a). Conclusion Claims 1-15 remain rejected. No claims are allowed. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to JUSTIN CHRISTOPHER SANCHEZ whose telephone number is (703)756-5336. The examiner can normally be reached Monday -Friday (0730-1700). Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, James H Alstrum-Acevedo can be reached at 571-272-5548. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. JUSTIN CHRISTOPHER SANCHEZ Examiner Art Unit 1622 /J.C.S./Examiner, Art Unit 1622 /JAMES H ALSTRUM-ACEVEDO/Supervisory Patent Examiner, Art Unit 1622
Read full office action

Prosecution Timeline

May 18, 2022
Application Filed
Jul 22, 2025
Non-Final Rejection — §102
Jan 27, 2026
Response Filed
Mar 17, 2026
Final Rejection — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12594271
COMBINATION THERAPY FOR CANCER
2y 5m to grant Granted Apr 07, 2026
Patent 12558348
BIOACTIVE PHYTOCHEMICALS
2y 5m to grant Granted Feb 24, 2026
Patent 12551463
DOSING OF A BRUTON'S TYROSINE KINASE INHIBITOR
2y 5m to grant Granted Feb 17, 2026
Patent 12551471
ABT-751 AND IONIZING RADIATION
2y 5m to grant Granted Feb 17, 2026
Patent 12527753
Cysteamine for the Treatment, Mitigation and Prevention of Coronaviral, e.g., SARS-CoV-2, Infections
2y 5m to grant Granted Jan 20, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
84%
Grant Probability
94%
With Interview (+10.0%)
3y 5m
Median Time to Grant
Moderate
PTA Risk
Based on 32 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month